(BHC) Bausch Health Companies - Ratings and Ratios

Exchange: TO • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA0717341071

BHC: Pharmaceuticals, Devices, Medicines, Treatments, Products, Healthcare

Bausch Health Companies Inc. (TO:BHC), formerly known as Valeant Pharmaceuticals International, Inc., is a diversified specialty pharmaceutical and medical device company with a robust global presence. The company operates through five distinct segments, each targeting specific therapeutic areas and markets. This diversification strategy is key for investors, as it spreads risk across various sectors and geographies.

The Salix segment focuses on gastroenterology in the U.S., offering treatments for conditions like inflammatory bowel disease. The International segment covers a broad range of products, including aesthetic devices, branded and generic pharmaceuticals, and OTC products, particularly strong in emerging markets. Solta Medical specializes in aesthetic devices, a sector with steady demand. The Diversified segment includes neurology products and ortho dermatologic solutions, while Bausch + Lomb, a well-recognized brand, excels in vision care and ophthalmic pharmaceuticals.

Headquartered in Laval, Canada, Bausch Health has a market cap of approximately 3964.92M CAD. The companys financials show a forward P/E of 1.79 and a P/S ratio of 0.42, indicating potential undervaluation. However, investors should consider the companys historical challenges, including debt and legal issues from its Valeant days, which have impacted its financial health.

Bausch Healths strength lies in its diversified portfolio and international reach. The companys focus on generics and OTC products provides stability, while its R&D investments aim to drive future growth. This balanced approach makes it an interesting consideration for those seeking exposure to both established and emerging healthcare markets.

Additional Sources for BHC Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

BHC Stock Overview

Market Cap in USD 2,386m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception

BHC Stock Ratings

Growth 5y -47.4%
Fundamental 38.9%
Dividend 5.20%
Rel. Strength -37.7
Analysts -
Fair Price Momentum 7.34 CAD
Fair Price DCF 78.94 CAD

BHC Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y 0.00%
Payout Consistency 20.8%

BHC Growth Ratios

Growth Correlation 3m -68.2%
Growth Correlation 12m 13.3%
Growth Correlation 5y -68%
CAGR 5y -15.74%
CAGR/Max DD 5y -0.18
Sharpe Ratio 12m -0.62
Alpha -43.43
Beta 0.596
Volatility 51.57%
Current Volume 187.8k
Average Volume 20d 254.1k
What is the price of BHC stocks?
As of April 03, 2025, the stock is trading at CAD 8.76 with a total of 187,840 shares traded.
Over the past week, the price has changed by -9.88%, over one month by -15.69%, over three months by -23.29% and over the past year by -36.66%.
Is Bausch Health Companies a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Bausch Health Companies (TO:BHC) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 38.92 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BHC as of April 2025 is 7.34. This means that BHC is currently overvalued and has a potential downside of -16.21%.
Is BHC a buy, sell or hold?
Bausch Health Companies has no consensus analysts rating.
What are the forecast for BHC stock price target?
According to ValueRays Forecast Model, BHC Bausch Health Companies will be worth about 7.9 in April 2026. The stock is currently trading at 8.76. This means that the stock has a potential downside of -9.47%.
Issuer Forecast Upside
Wallstreet Target Price 10.1 15.1%
Analysts Target Price - -
ValueRay Target Price 7.9 -9.5%